Lifetime and 1-Month Prevalence of Mental Disorders in Hebei Province, China: A Community-Based Cross-Sectional Study

Long Sun1,2†, Yunshu Zhang3†, Lijun Cui3, Jianfeng Li3, Lin Li3, Xiuli Sun3, Yongqiao Liu3, Lili Zhang3 and Keqing Li3*

1 Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, China, 2 NHC Key Lab of Health Economics and Policy Research, Shandong University, Jinan, China, 3 Hebei Provincial Mental Health Center, Baoding, China

Background: The prevalence of mental disorders is an important topic, which has been reported in different countries in the world. In China, some studies were also conducted to get the prevalence of mental disorders at the national level and in some metropolitan cities. However, the prevalence of mental disorders in Chinese underdeveloped provinces has not been reported internationally in recent decades. Due to the discrepancy in the social-economic development of different Chinese provinces, we also have reasons to believe the different prevalence of mental disorders between underdeveloped provinces and other provinces.

Method: A community-based cross-sectional study was conducted among community residents aged 18 years and older in Hebei province, China. We screened 20,884 community residents in this study, and a Structured Clinical Interview for Diagnostic and Statistical Manual (DSM-IV) Axis I disorders was used to make the diagnoses of mental disorders.

Results: The weighted lifetime prevalence of mental disorders was 15.87% (95% CI 15.38–16.38%), and the 1-month prevalence was 10.79% (95% CI 10.37–11.22%). Anxiety disorder ranked first in the classification of mental disorders for both lifetime (6.56%) and 1-month prevalence (6.25%). The weighted lifetime and 1-month region–gender–age-specific prevalence of mental disorders was also analyzed in this study.

Conclusions: Mental disorders have been an important issue in Chinese economically underdeveloped regions, and the prevalence was at a high level compared with the results in the 2000s. There are several serious challenges in the work of Chinese mental disorders, which should be paid more attention to.

Keywords: mental disorder, prevalence, community resident, cross-sectional study, China
INTRODUCTION

Mental disorders have been recognized as an important health problem in the world (1, 2). WHO reported that the burden of mental disorders continued to grow with significant impacts on health and major social, human rights, and economic consequences in all countries of the world (3). As we know, studies about the prevalence of mental disorders are fundamental works for controlling mental disorders, and it can help us to allocate the health resources and set up interventions, which should be explored in all the countries of the world (4, 5).

In the previous decades, the worldwide prevalence of mental disorders has been explored in the World Mental Health Survey (WMHS) (6, 7), and the prevalence of some kinds of mental disorders has been reported, such as social anxiety disorder (8), posttraumatic stress disorder (9), and so on (10, 11). Studies were also conducted in different countries to obtain the prevalence of mental disorders, such as the United State of America (USA) (12, 13), European countries (14), Singapore (15), Finland (16), India (17), and so on (18).

In China, there were also some studies, which explored the prevalence of mental disorders. Michael R Phillips et al. reported the prevalence of mental disorders in four provinces during 2001–2005 (19). Huang et al. reported the prevalence of mental disorders in 2013 (20). There were also some studies conducted in Chinese metropolitan cities (21, 22). All of these studies gave us more instructions for the theories and methods of epidemiological investigation in mental disorders (23). However, the prevalence of mental disorders in Chinese underdeveloped provinces has not been reported internationally in recent years. Due to the discrepancy in social-economic development in different Chinese provinces and the effect of economics on mental disorders (24), we have reasons to believe that the prevalence of mental disorders in the underdeveloped province may be also different.

To fill this gap, we conducted a community-based cross-sectional study to get the lifetime and 1-month prevalence of mental disorders in 2018 in Hebei province, China. Hebei is an economically underdeveloped province located in the middle of China, and the GDP per capita ranked 22nd in all of the 31 provinces of the Chinese mainland in 2018. The findings for this study are not only helpful for us to allocate the mental health resources and set up interventions in Hebei province, but they also can give us implications about the distribution of mental disorders in other Chinese economically underdeveloped regions.

METHOD

Study Design and Sample

Hebei is an economically underdeveloped province located in the middle of China. Between April and August 2016, we conducted a cross-sectional study to get the prevalence of mental disorders among community residents aged 18 years and older in Hebei province. In the current study, we interviewed 20,884 community residents, and 6,769 (32.41%) of them were selected to be diagnosed with mental disorders.

To obtain the prevalence of mental disorders in Hebei province, probability proportionate to size was used to sample for the current study. First, we calculated the sample size using the formula: \( N = \frac{Z_{1-\alpha/2}^2 p(1-p)}{\delta^2} \); where \( Z_{1-\alpha/2} \) (level of significance of 95% with two-tailed test) = 1.96; \( p \) (the prevalence of schizophrenia, one of the lowest prevalence in mental disorders) = 0.50% [referred from a previous cross-sectional epidemiological study in Hebei province (25)]; \( \delta \) (tolerable error) = 0.001. Then, the calculated minimum sample size was 19,112. Considering a response rate of 80%, we set the sample size as 24,000 in the current study. Second, the number of rural and urban samples was proportional to the region-specific population in each of the cities. Third, we randomly selected 1/3 of the districts and 1/5 of the counties in each city, and one street/town was also randomly selected in each district/county. Fourth, at the community and village level, one to three persons were randomly selected according to the sample size in this area. Finally, residents who have been living in the community/village for more than 6 months were chosen in this study. Then, we ranked these residents by age, and 1/10 of them were systematically selected to be interviewed. For the people who rejected the interview or could not be reached, their neighbors of the same gender and age were interviewed in the current study.

Interview Procedure

In the current study, the survey was organized in two stages. In the first stage, the subjects were screened by a Chinese version general health questionnaire (GHQ) and other eight questions about the risk factors of mental disorders. The risk factors were as follows: (1) poor physical health status in the recent month; (2) poor mental health status in the recent month; (3) thinking or doing things without control in the recent month; (4) restriction behaviors because of phobias in the recent month; (5) feeling nervous or anxious in the recent year; (6) experiencing troubles due to alcohol in the recent year; (7) seeking help because of psychological or psychiatric problems; (8) hospitalization because of psychological or psychiatric problems. Subjects who gave one or more positive responses among these eight questions were defined as “with risk factors.” For the scores of GHQ, we divided them into three groups (high-risk group, average-risk group, and low-risk group). The high-risk group contained subjects with GHQ scores equal to or higher than 4. The average-risk group contained subjects with GHQ scores equal to 2 or 3. The low-risk group contained subjects with GHQ scores equal to 0 or 1.

In the second stage, we selected the subjects to be screened by Structured Clinical Interview for Diagnostic and Statistical Manual (DSM-IV) Axis I disorders (SCID) according to the results of GHQ scores and risk factors of mental disorders. First, all subjects with risk factors or in the high-risk group were screened by SCID. Second, subjects in the average-risk group
with tail numbers 1–4 were screened by SCID. Third, subjects in the low-risk group with tail number 1 were screened by SCID. A similar selection method was also used in many previous studies (19, 26). The study flow diagram is presented in Figure 1. The Human Research Ethics Committee of Hebei Mental health Center approved the study protocol. Written informed consent was obtained from all the participants in the current study.

Quality Control
In the whole process of this study, strict quality control was employed to ensure the study quality. First, before the survey, all of the interviewers must be trained for 2 days to make sure they had fully understood the questionnaire and study flow. They were also asked to record the interview. Second, supervisors monitored throughout the survey and randomly checked the interview. Third, SCID diagnoses should be made by psychiatrists with more than 5 years of clinical experience. Fourth, all the questionnaires interviewed in the daytime should be checked again by other interviewers each night. Fifth, subjects with tail number 55 or 66 needed to be retested 5–7 days later by other interviewers in blind. For the subjects with different results, the psychiatrists needed to listen to the interview records and discussed the case to determine the final diagnosis. Finally, double-entry was used to make sure the precision of the data.

Measures
The Chinese version of the SCID was used to generate the diagnoses of mental disorders (27). The Chinese version of the SCID had been used in many epidemiological studies among Chinese populations, and it was identified with sound reliability and validity (19, 21).

The Chinese version of the General Health Questionnaire (GHQ) was used to select the subjects who were interviewed by SCID (28). This scale also had been used in the Chinese population for many years with good reliability and validity (29–31).

We also collected the gender, age, and region information of the subjects. Gender was indicated by male or female. Age was evaluated by the number of years, and we recorded it into four groups (18–34 years, 35–44 years, 45–59 years, and ≥60 years), which can be seen as an adolescent, young adults, midlife, and elder, respectively. The region was assessed as urban or rural where they lived. All of the subjects should live in the current region for more than 6 months.

Statistical Methods
IBM SPSS statistics 24.0 for Windows (web edition) and Microsoft Office Excel 2016 for Windows were used for the data analyses. Due to the rules of data collection, we needed to weigh the samples to get the prevalence of mental disorders. The weight used in the current study was generated by three steps (32). In the first step, the subjects with SCID diagnoses (6,769 subjects) were weighted into the number of participants (20,884 subjects) based on the selection of SCID interviews. In the second step, poststratification weights were used to generate the weight of gender–age–region distribution in Hebei province. The distribution of gender, age, and region were based on the data of the 1% population sampling survey in 2015 (33). Finally, we multiplied these two weights to calculate the final weight used for the data analyses.

A chi-square test was applied to compare the significance among different social-demographic populations. The 95% confidence interval for the proportion was calculated by the Wilson score method without continuity correction (34). All tests were two-tailed and a \( p \leq 0.05 \) was considered statistically significant.

RESULTS
In the current study, 23,675 participants were invited to participate in the survey, and 20,884 (88.21%) subjects agreed and completed the questionnaires. With the rules about the scores of GHQ and risk factors of mental disorders, 6,769 (32.41%) of them were selected to diagnose by SCID, and 2,371 (35.03%) subjects were positively diagnosed. Figure 1 was the study flow, which displayed the detailed interview process. We also analyzed the social-demographic information in each stage in Table 1.

After weighing the sample, we calculated the lifetime and 1-month prevalence of mental disorders. The results showed that the weighted lifetime prevalence of mental disorders was 15.87% (95% CI 15.38–16.38%), and the 1-month prevalence was 10.79% (95% CI 10.37–11.22%). Anxiety disorder ranked first in the classification of mental disorders for both lifetime (6.56%) and 1-month prevalence (6.25%). For lifetime prevalence, the following order was substance use disorder (6.20%), mood disorder (4.58%), psychotic disorders (1.03%), and other mental disorders (0.06%). For 1-month prevalence, the following order was substance use disorder (3.69%), mood disorder (3.06%), psychotic disorders (0.74%), and other mental disorders (0.32%). For the detailed diagnoses, the top five lifetime persons were alcohol use disorders (5.93%), anxiety disorder not otherwise specified (NOS) (3.80%), major depressive disorder (2.93%), specific phobias (1.39%), and depressive disorder NOS (0.99%). Moreover, the top five 1-month disorders were anxiety disorder NOS (3.70%), alcohol use disorders (3.51%), major depressive disorder (1.29%), specific phobias (1.16%), and depressive disorder NOS (0.79%). The detailed lifetime and 1-month prevalence of mental disorders are presented in Table 2.

We also calculated the gender-specific lifetime and 1-month prevalence of mental disorders. The lifetime and 1-month prevalence of mood disorders and anxiety disorders among women were higher, but the prevalence of substance use disorders was lower. For other mental disorders, the lifetime prevalence was higher in men, but the 1-month prevalence was lower. For men, the top five diagnoses of the weighted lifetime prevalence of mental disorders were alcohol use disorders (11.41%), anxiety disorder NOS (2.77%), major depressive disorder (2.23%), specific phobias (1.00%), and depressive disorder NOS (0.83%). However, for women, posttraumatic stress disorder (1.21%) was in the top five diagnoses instead of alcohol use disorders (0.48%). When we considered the 1-month prevalence among men, the top five were alcohol use disorders (6.80%), anxiety disorder NOS (2.72%), specific phobias (0.82%), major depressive disorder NOS (0.79%), and depressive disorder NOS (0.79%).
TABLE 1 | Social-demographic characteristics of the participants (n = 20,884).

| Variable          | Valid sample [n1 (n1/n)] | Valid SCID screening [n2 (n2/n1)] | Valid SCID diagnoses [n3 (n3/n2)] |
|-------------------|--------------------------|-----------------------------------|----------------------------------|
| Gender            |                          |                                   |                                  |
| Male              | 10,703 (51.25%)          | 3,004 (28.07%)                    | 1,086 (36.12%)                   |
| Female            | 10,181 (48.75%)          | 3,765 (36.98%)                    | 1,286 (34.16%)                   |
| Age (years old)   |                          |                                   |                                  |
| 15–34             | 5,011 (23.99%)           | 981 (19.58%)                      | 249 (25.38%)                     |
| 35–44             | 3,427 (16.41%)           | 818 (23.87%)                      | 254 (31.05%)                     |
| 45–59             | 6,216 (29.76%)           | 2,251 (36.21%)                    | 867 (38.52%)                     |
| ≥60               | 6,230 (29.83%)           | 2,719 (43.64%)                    | 1,001 (36.82%)                   |
| Region            |                          |                                   |                                  |
| Urban             | 6,056 (29.00%)           | 1,935 (31.95%)                    | 754 (38.97%)                     |
| Region            | 14,828 (71.00%)          | 4,834 (32.60%)                    | 1,617 (33.45%)                   |
| Total             | 20,884 (100.00%)         | 6,769 (32.41%)                    | 2,371 (35.03%)                   |

We also compared the prevalence of each diagnosis between men and women, and most of them were different between men and women (p<0.05). The detailed information was shown in Table 3.

In Tables 4, 5, we analyzed the weighted lifetime and 1-month age-specific prevalence of mental disorders, respectively. We also compared the prevalence among the different age groups in these two tables. Generally, both lifetime and 1-month prevalence of mood disorders and anxiety disorders increased with age. For substance use disorder, the lifetime and 1-month prevalence also increased with the age, with an exception of elders (aged ≥60 years). For people aged 18–34 years and 35–44 years, the top five diagnoses of the weighted lifetime prevalence were alcohol use disorders (4.43%, 4.90%), anxiety disorder NOS (2.44%, 3.56%), specific phobias (1.24%, 0.71%), major depressive disorder (1.21%, 1.70%), and schizophrenia (0.51%, 1.23%). For people aged 45–59 years and ≥60 years, depressive disorders (0.81%), depressive disorder NOS (0.62%) and schizophrenia (0.62%). Nevertheless, for women, dysthymic disorder (1.04%) displaced alcohol use disorders (0.24%) and rose into the top five diagnoses. We also compared the prevalence of each diagnosis between men and women, and most of them were different between men and women (p<0.05). The detailed information was shown in Table 3.
| Mental disorders                                      | Unweighted n | Weighted n | Weighted % (95% CI) | Unweighted n | Weighted n | Weighted % (95% CI) |
|-------------------------------------------------------|--------------|------------|---------------------|--------------|------------|---------------------|
| Mood disorders                                        | 802          | 957        | 4.58 (4.31, 4.87)   | 637          | 640        | 3.06 (2.84, 3.31)   |
| Bipolar I disorder                                    | 30           | 32         | 0.15 (0.11, 0.22)   | 15           | 16         | 0.08 (0.05, 0.12)   |
| Bipolar II disorders                                  | 8            | 8          | 0.04 (0.02, 0.08)   | 7            | 7          | 0.03 (0.02, 0.07)   |
| Other bipolar disorders                               | 8            | 15         | 0.07 (0.04, 0.12)   | 6            | 7          | 0.03 (0.02, 0.07)   |
| Major depressive disorder                             | 499          | 612        | 2.93 (2.71, 3.17)   | 289          | 270        | 1.29 (1.15, 1.46)   |
| Dysthymic disorder*                                   | –            | –          | –                   | 135          | 138        | 0.66 (0.56, 0.78)   |
| Depressive disorder NOS                               | 165          | 207        | 0.99 (0.87, 1.13)   | 141          | 164        | 0.79 (0.67, 0.91)   |
| Mood disorder due to GMC                              | 98           | 90         | 0.43 (0.35, 0.53)   | 77           | 72         | 0.34 (0.27, 0.43)   |
| Substance-induced mood disorder                       | 5            | 5          | 0.02 (0.01, 0.06)   | 3            | 3          | 0.01 (<0.01, 0.04)  |
| Anxiety disorders                                     | 1,043        | 1,370      | 6.56 (6.23, 6.90)   | 1,015        | 1,306      | 6.25 (5.93, 6.59)   |
| Panic disorder                                         | 88           | 89         | 0.43 (0.35, 0.52)   | 68           | 72         | 0.34 (0.27, 0.43)   |
| Agoraphobia without panic                              | 19           | 21         | 0.10 (0.07, 0.15)   | 15           | 17         | 0.08 (0.05, 0.13)   |
| Social phobia                                         | 19           | 34         | 0.16 (0.12, 0.23)   | 12           | 10         | 0.05 (0.03, 0.09)   |
| Specific phobias                                      | 177          | 290        | 1.29 (1.24, 1.56)   | 139          | 242        | 1.16 (1.02, 1.31)   |
| Obsessive compulsive disorder                         | 29           | 31         | 0.15 (0.10, 0.21)   | 24           | 21         | 0.10 (0.07, 0.15)   |
| Post-traumatic stress disorder                        | 118          | 161        | 0.77 (0.68, 0.90)   | 41           | 58         | 0.28 (0.21, 0.36)   |
| Generalized anxiety disorder*                         | –            | –          | –                   | 122          | 128        | 0.61 (0.52, 0.73)   |
| Anxiety disorders due to GMC                          | 57           | 52         | 0.25 (0.19, 0.33)   | 54           | 48         | 0.22 (0.17, 0.29)   |
| Substance-induced anxiety disorder                    | 6            | 6          | 0.03 (0.01, 0.06)   | 6            | 6          | 0.03 (0.01, 0.06)   |
| Anxiety disorder NOS                                  | 620          | 793        | 3.80 (3.55, 4.06)   | 607          | 772        | 3.70 (3.45, 3.96)   |
| Substance use disorders                               | 621          | 1,294      | 6.20 (6.88, 6.53)   | 400          | 771        | 3.69 (3.44, 3.96)   |
| Alcohol use disorders                                 | 565          | 1,239      | 5.93 (6.62, 6.26)   | 357          | 734        | 3.51 (3.27, 3.77)   |
| Sedative/hypnotic/antianxiety drug use disorders      | 51           | 51         | 0.24 (0.19, 0.32)   | 42           | 37         | 0.18 (0.13, 0.24)   |
| Other substance use disorders†                        | 10           | 9          | 0.04 (0.02, 0.08)   | 7            | 10         | 0.05 (0.03, 0.09)   |
| Psychotic disorders                                   | 168          | 215        | 1.03 (0.90, 1.18)   | 125          | 155        | 0.74 (0.63, 0.87)   |
| Schizophrenia                                         | 124          | 150        | 0.72 (0.61, 0.84)   | 99           | 125        | 0.60 (0.50, 0.71)   |
| Schizophreniform disorder                             | 2            | 6          | 0.03 (0.01, 0.06)   | 1            | 5          | 0.02 (0.01, 0.06)   |
| Schizoaffective disorder                              | 2            | 2          | 0.01 (<0.01, 0.03)  | 2            | 2          | 0.01 (<0.01, 0.03)  |
| Delusional disorder                                   | 15           | 15         | 0.07 (0.04, 0.12)   | 7            | 6          | 0.03 (0.01, 0.06)   |
| Brief psychotic disorder                              | 4            | 3          | 0.01 (<0.01, 0.04)  | 0            | 0          | 0.00 (0.00, 0.00)   |
| Psychotic disorder due to GMC                         | 5            | 5          | 0.02 (0.01, 0.06)   | 4            | 4          | 0.02 (0.01, 0.05)   |
| Substance-induced psychotic disorder                  | 1            | 1          | <0.01 (<0.01, 0.03) | 1            | 1          | <0.01 (<0.01, 0.03) |
| Psychotic disorder NOS                                | 15           | 33         | 0.16 (0.11, 0.22)   | 11           | 12         | 0.06 (0.03, 0.10)   |
| Other mental disorders                                | 4            | 12         | 0.06 (0.03, 0.10)   | 64           | 66         | 0.32 (0.25, 0.40)   |
| Somatization disorder*                                | –            | –          | –                   | 8            | 9          | 0.04 (0.02, 0.08)   |
| Pain disorder*                                        | –            | –          | –                   | 32           | 29         | 0.14 (0.10, 0.20)   |
| Somatof orm disorder NOS*                             | –            | –          | –                   | 11           | 9          | 0.04 (0.02, 0.08)   |
| Hypochondriasis*                                      | –            | –          | –                   | 7            | 6          | 0.03 (0.01, 0.06)   |
| Dystmorphic disorder*                                 | –            | –          | –                   | 1            | 1          | <0.01 (<0.01, 0.03) |
| Adjustment disorder*                                  | –            | –          | –                   | 6            | 5          | 0.02 (0.01, 0.06)   |
| Eating disorders‡                                      | 1            | 1          | <0.01 (<0.01, 0.03) | 1            | 1          | <0.01 (<0.01, 0.03) |
| Other DSM axis I disorders                            | 3            | 10         | 0.05 (0.03, 0.09)   | 3            | 10         | 0.05 (0.03, 0.09)   |
| Any mental disorder (excluding dementia)             | 2,219        | 3,315      | 15.87 (15.38, 16.38) | 1,881        | 2,253      | 10.79 (10.37, 11.22) |

CI, Confidence interval; NOS, Not otherwise specified; GMC, General medical condition.

*: Only have a current diagnosis.
‡: Cannabis, stimulant, opioid, cocaine, hallucinogen, multiple drugs, and other substance use disorders; †: Anorexia nervosa, bulimia nervosa, and binge eating disorders.

Disorder NOS replaced schizophrenia and rose into the top five diagnoses. When we conducted to the weighted 1-month prevalence of mental disorders, the top five diagnoses for people aged 18–34 years were alcohol use disorders (2.62%), anxiety disorder NOS (2.37%), specific phobias (1.13%), schizophrenia (0.44%), and depressive disorder NOS (0.38%). For people...
TABLE 3 | Weighted lifetime and 1-month prevalence of mental disorders by gender in Hebei province, China (n = 20,884).

| Mental disorders | Lifetime prevalence | Male [% (95% CI)] | Female [% (95% CI)] | p | 1-month prevalence | Male [% (95% CI)] | Female [% (95% CI)] | p |
|------------------|---------------------|------------------|---------------------|---|---------------------|------------------|------------------|---|
| Mood disorders   |                     |                  |                     |   |                     |                  |                  |   |
| Bipolar I disorder | 0.15 (0.09, 0.25) | 0.15 (0.09, 0.25) | 0.992 |     |                     |                  |                  |   |
| Bipolar II disorder | 0.07 (0.03, 0.14) | 0.02 (0.01, 0.07) | 0.109 |     |                     |                  |                  |   |
| Major depressive disorder | 2.23 (1.96, 2.53) | 3.63 (3.29, 4.01) | <0.001 |     |                     |                  |                  |   |
| Dysthymic disorder* |                 |                  |                     |   |                     |                  |                  |   |
| Depression disorder NOS | 0.83 (0.67, 1.02) | 1.16 (0.97, 1.38) | 0.016 |     |                     |                  |                  |   |
| Mood disorder due to GMC | 0.31 (0.22, 0.43) | 0.55 (0.43, 0.72) | 0.006 |     |                     |                  |                  |   |
| Substance-induced mood disorder | 0.04 (0.01, 0.10) | 0.01 (<0.01, 0.05) | 0.178 |     |                     |                  |                  |   |
| Anxiety disorders |                     |                  |                     |   |                     |                  |                  |   |
| Panic disorder | 0.16 (0.10, 0.26) | 0.69 (0.55, 0.87) | <0.001 |     |                     |                  |                  |   |
| Agoraphobia without panic | 0.02 (0.01, 0.07) | 0.19 (0.12, 0.30) | <0.001 |     |                     |                  |                  |   |
| Social phobia | 0.22 (0.15, 0.33) | 0.11 (0.06, 0.19) | 0.038 |     |                     |                  |                  |   |
| Specific phobias | 1.00 (0.82, 1.21) | 1.78 (1.54, 2.05) | <0.001 |     |                     |                  |                  |   |
| Obsessive compulsive disorder | 0.13 (0.08, 0.23) | 0.16 (0.10, 0.26) | 0.597 |     |                     |                  |                  |   |
| Generalized anxiety disorder* |                 |                  |                     |   |                     |                  |                  |   |
| Anxiety disorders due to GMC | 0.19 (0.12, 0.30) | 0.31 (0.22, 0.43) | 0.098 |     |                     |                  |                  |   |
| Substance-induced anxiety disorder | 0.04 (0.01, 0.10) | 0.02 (0.01, 0.07) | 0.412 |     |                     |                  |                  |   |
| Anorexia nervosa, bulimia nervosa, and binge eating disorders. |                 |                  |                     |   |                     |                  |                  |   |
| Sedative/hypnotic/anxiolytic drug use disorders | 0.23 (0.15, 0.34) | 0.26 (0.18, 0.38) | 0.684 |     |                     |                  |                  |   |
| Other substance use disorders† |                 |                  |                     |   |                     |                  |                  |   |
| Psychotic disorders | 1.07 (0.89, 1.29) | 0.98 (0.81, 1.19) | 0.520 |     |                     |                  |                  |   |
| Schizophrenia | 0.71 (0.57, 0.89) | 0.74 (0.59, 0.92) | 0.823 |     |                     |                  |                  |   |
| Schizophreniform disorder | 0.06 (0.03, 0.13) | 0.00 (0.00, 0.00) | 0.014 |     |                     |                  |                  |   |
| Schizoaffective disorder | 0.00 (0.00, 0.00) | 0.02 (0.01, 0.07) | 0.500 |     |                     |                  |                  |   |
| Delusional disorder | 0.03 (0.01, 0.08) | 0.11 (0.07, 0.20) | 0.020 |     |                     |                  |                  |   |
| Brief psychotic disorder | 0.02 (0.01, 0.07) | 0.02 (0.01, 0.07) | 1.000 |     |                     |                  |                  |   |
| Psychotic disorder due to GMC | 0.03 (0.01, 0.08) | 0.02 (0.01, 0.07) | 0.687 |     |                     |                  |                  |   |
| Substance-induced psychotic disorder | 0.00 (0.00, 0.00) | 0.01 (<0.01, 0.05) | 1.000 |     |                     |                  |                  |   |
| Psychotic disorder NOS | 0.24 (0.16, 0.35) | 0.09 (0.05, 0.16) | 0.006 |     |                     |                  |                  |   |
| Other mental disorders | 0.09 (0.05, 0.16) | 0.02 (0.01, 0.07) | 0.034 |     |                     |                  |                  |   |
| Somatization disorder* |                 |                  |                     |   |                     |                  |                  |   |
| Pain disorder* |                    |                  |                     |   |                     |                  |                  |   |
| Somatoform disorder NOS* |                 |                  |                     |   |                     |                  |                  |   |
| Hypochondriasis* |                    |                  |                     |   |                     |                  |                  |   |
| Dystrophic disorder* |                    |                  |                     |   |                     |                  |                  |   |
| Adjustment disorder* |                    |                  |                     |   |                     |                  |                  |   |
| Eating disorders‡ | 0.00 (0.00, 0.00) | 0.01 (<0.01, 0.05) | 0.318 |     |                     |                  |                  |   |
| Other DSM axis I disorders | 0.09 (0.05, 0.16) | 0.01 (<0.01, 0.05) | 0.011 |     |                     |                  |                  |   |
| Any mental disorder (excluding dementia) | 18.13 | 13.62 | <0.001 |     |                     |                  |                  |   |

CI, Confidence interval; NOS, Not otherwise specified; GMC, General medical condition.
*: Only have a current diagnosis. †: Cannabis, stimulant, opioid, cocaine, hallucinogen, multiple drugs, and other substance use disorders; ‡: Anorexia nervosa, bulimia nervosa, and binge eating disorders.
aged 35–44 years, the order changed into alcohol use disorders (3.53%), anxiety disorder NOS (3.48%), schizophrenia (1.01%), major depressive disorder (0.68%), specific phobias (0.63%), and depressive disorder NOS (0.63%). For people aged 45–59 years, the order was alcohol use disorders (4.45%), anxiety disorder NOS (4.15%), major depressive disorder (1.93%), specific phobias (1.15%), and depressive disorder NOS (1.03%). For elders (≥60 years), the order was anxiety disorder NOS (5.34%), alcohol use disorders (3.61%), major depressive disorder (2.44%), Specific phobias (1.69%), and dysthymic disorder (1.32%).

Region-specific prevalence is shown in Table 6. We also compared the different prevalence between rural and urban regions. All of the classifications of mental disorders were statistically significant (p < 0.05) between the rural and urban regions, apart from other mental disorders. The weighted lifetime and 1-month prevalence of mood disorders and psychotic disorders were higher in the rural region, but the prevalence of anxiety disorders and substance use disorders was lower. Alcohol use disorders, anxiety disorder NOS, major depressive disorder, specific phobias, depressive disorder NOS were the top five diagnoses in the urban and rural region.

In Figures 2, 3, we calculated the weighted lifetime and 1-month region–gender–age-specific prevalence of mental disorders.
The prevalence of mood disorders was higher in the urban region of Hebei province. In the rural region, the prevalence of anxiety disorders in women was the most serious mental disorders. The results implied that substance use disorders in men and anxiety disorders in women were the most serious problems in Hebei province. In the rural region, the prevalence of anxiety increased rapidly after people aged 35 years. The prevalence of mood disorders was higher in the urban region and increased with age. For psychotic disorders, the prevalence in rural males aged 18–44 years and rural females aged 60 years was higher.

Finally, we analyzed the comorbidity of the weighted lifetime and 1-month diagnoses of mental disorders in Table 7. For...
| Mental disorders                                      | Lifetime prevalence | 1-month prevalence | p    |
|------------------------------------------------------|---------------------|--------------------|------|
|                                                      | Urban [% (95% CI)]  | Rural [% (95% CI)] |      |
| Mood disorders                                        | 3.93 (3.42, 4.52)   | 4.78 (4.46, 5.12)  | 0.014|
| Bipolar I disorder                                   | 0.17 (0.08, 0.33)   | 0.15 (0.10, 0.22)  | 0.776|
| Bipolar II disorders                                 | 0.00 (0.00, 0.00)   | 0.05 (0.03, 0.10)  | 0.123|
| Other bipolar disorders                              | 0.06 (0.02, 0.18)   | 0.07 (0.04, 0.13)  | 0.790|
| Major depressive disorder                            | 2.51 (2.10, 2.99)   | 3.06 (2.81, 3.34)  | 0.047|
| Dysthymic disorder*                                  | –                   | –                  |      |
| Depression disorder NOS                              | 0.84 (0.62, 1.14)   | 1.04 (0.89, 1.21)  | 0.220|
| Mood disorder due to GMC                             | 0.36 (0.22, 0.57)   | 0.45 (0.36, 0.57)  | 0.365|
| Substance-induced mood disorder                       | 0.02 (<0.01, 0.12)  | 0.03 (0.01, 0.07)  | 0.717|
| Anxiety disorders                                     | 7.91 (7.17, 8.71)   | 6.17 (5.81, 6.55)  | <0.001|
| Panic disorder                                        | 0.31 (0.19, 0.52)   | 0.46 (0.37, 0.58)  | 0.174|
| Agoraphobia without panic                             | 0.15 (0.07, 0.30)   | 0.09 (0.06, 0.15)  | 0.319|
| Social phobia                                         | 0.06 (0.02, 0.18)   | 0.19 (0.14, 0.27)  | 0.051|
| Specific phobias                                      | 1.38 (1.09, 1.75)   | 1.39 (1.22, 1.58)  | 0.966|
| Obsessive compulsive disorder                         | 0.17 (0.08, 0.33)   | 0.14 (0.10, 0.21)  | 0.699|
| Post-traumatic stress disorder                        | 0.23 (0.13, 0.41)   | 0.93 (0.79, 1.09)  | <0.001|
| Generalized anxiety disorder                          | –                   | –                  |      |
| Anxiety disorders due to GMC                          | 0.19 (0.10, 0.36)   | 0.27 (0.20, 0.36)  | 0.338|
| Substance-induced anxiety disorder                    | 0.00 (0.00, 0.00)   | 0.04 (0.02, 0.08)  | 0.348|
| Anxiety disorder NOS                                  | 5.92 (5.29, 6.62)   | 3.17 (2.91, 3.46)  | <0.001|
| Substance use disorders                               | 8.47 (7.71, 9.29)   | 5.52 (5.18, 5.88)  | <0.001|
| Alcohol use disorders                                 | 8.03 (7.30, 8.84)   | 5.30 (4.97, 5.66)  | <0.001|
| Sedative/hypnotic/anxiolytic drug use disorders       | 0.42 (0.27, 0.65)   | 0.19 (0.13, 0.27)  | 0.006|
| Other substance use disorders†                        | 0.02 (<0.01, 0.12)  | 0.05 (0.03, 0.10)  | 0.694|
| Psychotic disorders                                   | 0.59 (0.41, 0.85)   | 1.16 (1.01, 1.34)  | 0.001|
| Schizophrenia                                         | 0.44 (0.29, 0.67)   | 0.80 (0.67, 0.96)  | 0.009|
| Schizophreniform disorder                             | 0.00 (0.00, 0.00)   | 0.04 (0.02, 0.08)  | 0.348|
| Schizoaffective disorder                              | 0.00 (0.00, 0.00)   | 0.01 (<0.01, 0.05) | 1.000|
| Delusional disorder                                  | 0.00 (0.00, 0.00)   | 0.09 (0.06, 0.15)  | 0.030|
| Brief psychotic disorder                              | 0.02 (<0.01, 0.12)  | 0.02 (0.01, 0.05)  | 1.000|
| Psychotic disorder due to GMC                         | 0.06 (0.02, 0.18)   | 0.01 (<0.01, 0.05) | 0.082|
| Substance-induced psychotic disorder                  | 0.00 (0.00, 0.00)   | 0.01 (<0.01, 0.04) | 1.000|
| Psychotic disorder NOS                                | 0.06 (0.02, 0.18)   | 0.19 (0.13, 0.27)  | 0.059|
| Other mental disorders                                | 0.04 (0.01, 0.15)   | 0.06 (0.03, 0.11)  | 1.000|
| Somatization disorder*                                | –                   | –                  |      |
| Pain disorder*                                        | –                   | –                  |      |
| Hypochondriasis*                                      | –                   | –                  |      |
| Dysmorphic disorder*                                  | –                   | –                  |      |
| Adjustment disorder*                                  | –                   | –                  |      |
| Eating disorders‡                                      | 0.02 (<0.01, 0.12)  | 0.00 (0.00, 0.00)  | 0.029|
| Other DSM axis I disorders                            | 0.00 (0.00, 0.00)   | 0.06 (0.03, 0.11)  | 0.130|
| Any mental disorder (excluding dementia)             | 19.06               | 14.93              | <0.001|

CI, Confidence interval; NOS, Not otherwise specified; GMC, General medical condition.
* Only have a current diagnosis. † Cannabis, stimulant, opioid, cocaine, hallucinogen, multiple drugs, and other substance use disorders; ‡ Anorexia nervosa, bulimia nervosa, and binge eating disorders.
lifetime diagnoses, the results showed that there were 491 (2.35%) subjects who met the diagnoses criteria for two, and 76 (0.36%) subjects met the diagnoses criteria for three or more. Similarly, 344 (1.65%) subjects met the diagnoses criteria for two, and 71 (0.34%) subjects met the diagnoses criteria for three or more for the 1-month diagnoses.
TABLE 7 | Comorbidity of the weighted lifetime and 1-month diagnoses of mental disorders [n (%)].

| Number of diagnoses | Weighted lifetime diagnoses | Weighted 1-month diagnoses |
|---------------------|-----------------------------|----------------------------|
| 0                   | 17,569 (84.13)              | 18,331 (87.78)             |
| 1                   | 2,749 (13.16)               | 2,138 (10.24)              |
| 2                   | 491 (2.35)                  | 344 (1.66)                 |
| ≥3                  | 76 (0.36)                   | 71 (0.34)                  |
| Total               | 20,884 (100.00)             | 20,884 (100.00)            |

**DISCUSSION**

The current study was conducted in Hebei province, an economically underdeveloped region in China, to get the lifetime and 1-month prevalence of mental disorders. The results found that the lifetime prevalence of mental disorders was 15.87% (95% CI: 15.38–16.38%) and the 1-month prevalence of mental disorders was 10.79% (95% CI: 10.37–11.22%). Comparing with the Chinese studies, it is similar to the results in CMHS (16.6%, 9.3%) (20), but it is higher than the results in TJMHS (23.6%, 12.8%) (21). The reason may be explained by regional differences. The current study was interviewed in an underdeveloped province, but TJMHS was implemented in metropolitan China. People who lived in metropolitan had a higher level of life and work stress, which are risk factors for mental disorders (35).

However, when we compared the findings with many other Western countries, it is much lower. According to the WHO’s World Mental Health Survey, the lifetime prevalence of mental disorders ranged from 12.0% in Nigeria to 47.4% in the USA, and most of the available data are higher than the prevalence in the current study (36). In the NCS-R study in the USA, the lifetime prevalence of mental disorders was 26.2% in 2001–2002 (37), and it is higher than the prevalence in the current study. The Global Burden of Disease (GBD) 2017 showed that 11,46,401.2 thousand people were with mental disorders and substance use disorders. They mean that the prevalence of mental disorders was about 15%. This data was similar to our findings (16.6%).

In the current study, we also found that the prevalence of anxiety disorders was highest in all of the classifications of mental disorders. It is consistent with recent Chinese studies in CMHS (20), TJMHS (21). However, in the last decades, a study in four Chinese provinces supported mood disorders rank first in the classification of mental disorders (19). In recent years, China is one of the few countries with high-speed development in the world, and Chinese society changes very fast. People need to adapt to the changing society, which is also a risk factor for anxiety disorders (38). This may be a reason for changing the order of anxiety and mood disorders.

The prevalence of some diagnoses with NOS is at a high level in the results, such as anxiety NOS, depressive disorder NOS. This may be caused by the characteristics of mental disorders NOS. Sometimes, we can also see them as the “subthreshold disorders (39, 40),” but they are also at a higher risk of developing full-down psychiatric disorders (41). Thus, the findings imply to us that there are many residents at high risk of full-down psychiatric disorders, and we need to pay more attention and work on them to control the development of mental disorders.

Gender differences were also supported for other kinds of mental disorders, and the prevalence for men is higher than for women. It was mainly caused by substance use disorders, and the other kinds of mental disorders were higher for women. The results align with the previous studies in China and other countries (42, 43). In China, the differences in the lifetime prevalence of substance use disorders are larger than most of the other countries (11.61 vs. 0.79%), and there are more male alcohol drinkers than females. The gap is also very big, especially in the north of China (44, 45). One of the reasons is the Confucian culture in China. The gender differences for other kinds of mental disorders, it may be caused by the sex hormone (46, 47).

We also found that mood and anxiety disorders increased with age, but substance use and psychotic disorders were higher in residents aged 35–44 years. In the rural region, mood disorders and psychotic disorders were higher, and anxiety disorders and substance use disorders were higher in the urban region. Similar findings were also found for the 1-month prevalence of mental disorders expect for substance use disorders. All of these findings were consistent with previous studies in China and other countries (7, 20, 48). Comparing with the rural region, people who live in the urban region have heavier work-load and life stress (49, 50), and they may be at higher risk of mental disorders. Substance use disorders, one way to deal with stress, may also be in higher-level for rural residents. However, for rural residents, most of them were lower educated, and they were lack of coping skills, which are also risk factors for mood disorders and psychotic disorders (51, 52).

We also analyzed the comorbidity of the diagnoses for the mental disorders, and the results showed that most of the residents were diagnosed with one mental disorder (13.16% for lifetime prevalence and 10.4% for 1-month prevalence). Few residences can be diagnosed with more than two kinds of mental disorders (2.71% for lifetime prevalence and 1.99% for 1-month prevalence). They are lower than the percentages found from the NCSR (3.8%) (37). As we discussed before, the prevalence of mental disorders was lower in other Western countries, and the severity of mental disorders was not at a high level. Thus, the comorbidity of the diagnoses for the mental disorders was lower than findings from other studies.

There are some limitations, which should be considered when we interpret the findings. First, the sample in the current were community residents aged 18 years and older, and people aged lower than 18 years and who lived in construction sites, armed services, schools, and hospitals were not included in the design. Second, all of the diagnoses were from SCID axis I, and the Axis II diagnoses and dementia were not reported in the current study. Third, the sample size was calculated by the prevalence of schizophrenia, and the prevalence of some mental disorders with lower prevalence is not confident in the current study. Finally, the time frame for the current prevalence was 1 month, and the results cannot be compared with others with different time frames.

Despite these limitations, this is the first large-scale mental health epidemiological study, which conducted in a Chinese economically underdeveloped province using SCID diagnoses.
The results are more confident compared with other studies in China in the recent 10 years because of the instruments and strict quality control. The results also can help us to allocate health resources and set up interventions.

**DATA AVAILABILITY STATEMENT**

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by The Human Research Ethics Committee of Hebei Mental Health Center. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Collaborators GDaH. Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet*. (2017) 390:1260–344. doi: 10.1016/S0140-6736(17)32130-X

2. Patel V, Saxena S, Lund C, Thornicroft G, Baingana F, Bolton P, et al. The Lancet Commission on global mental health and sustainable development. *Lancet*. (2018) 392:1553–98. doi: 10.1016/s0140-6736(18)31612-x

3. WHO. Mental disorders: key facts: WHO (2019). Available online at: https://www.who.int/news-room/fact-sheets/detail/mental-disorders.

4. Clark HW, Power AK, Le Fauve CE, Lopez EI. Policy and implications for the Global Burden of Disease Study 2016. *Lancet*. (2018) 392:1553–98. doi: 10.1016/s0140-6736(18)31612-x

5. Phillips MR. Can China’s new mental health law substantially reduce the burden of illness attributable to mental disorders? *Lancet*. (2013) 381:1964–6. doi: 10.1016/S0140-6736(13)61177-0

6. Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, Ormel J, et al. The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. *Epidemiol Psychiatr Soc*. (2009) 18:23–33. doi: 10.1017/s1121182x09001421

7. Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA*. (2004) 291:2581–90. doi:10.1001/jama.291.21.2581

8. Stein DJ, Lim CCW, Roest AM, de Jonge P, Aguilar-Gaxiola S, Al-Hamzawi A, et al. The cross-national epidemiology of social anxiety disorder: Data from the World Mental Health Survey Initiative. *BMC Med*. (2017) 15:143. doi:10.1186/s12916-017-0889-2

9. Koenen KC, Ratnathitharam A, Ng L, McLaughlin KA, Bromet EJ, Stein DJ, et al. Posttraumatic stress disorder in the World Mental Health Surveys. *Psychol Med*. (2017) 47:2260–74. doi:10.1017/s003329170000708

10. Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, et al. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. *Schizophr Bull*. (2018) 44:1195–203. doi:10.1093/schbul/bsy058

11. Huang Y, Kotov R, de Girolamo G, Petti A, Angermeyer M, Benjet C, et al. DSM-IV personality disorders in the WHO World Mental Health Surveys. *Br J Psychiatry*. (2009) 195:46–53. doi: 10.1192/bjp.bp.108.058552

12. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Ehleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. *Results from the National Comorbidity Survey Replication*. (1994) 51:8–19. doi:10.1001/archpsyc.1994.03950010008002

13. Kessler RC, Merikangas KR. The National Comorbidity Survey Replication (NCS-R): background and aims. *Int J Methods Psychiatr Res*. (2004) 13:60–8.

14. Kessler RC. The global burden of anxiety and mood disorders: putting the European Study of the Epidemiology of Mental Disorders (ESEMeD) findings into perspective. *J Clin Psychiatry*. (2007) 68:10–9.

15. Subramaniam M, Abdin E, Vaingankar J, Shafie S, Chua BY, Sambasivam R, et al. Tracking the mental health of a nation: prevalence and correlates of mental disorders in the second Singapore mental health study. *Epidemiol Psychiatr Sci*. (2019) 2019:1–10. doi:10.1177/20457960198000179

16. Lehtinen V, Joukamaa M, Lahtela K, Raitasalo R, Jyrkinen E, Maetela J, et al. Prevalence of mental disorders among adults in Finland: basic results from the Mini Finland Health Survey. *Acta Psychiatr Scand*. (1990) 81:418–25.

17. Ganguli HC. Epidemiological findings on prevalence of mental disorders in India. *Indian J Psychiatry*. (2000) 42:14–20.

18. Xiang YT, Zhang Q, Wang G, Zeng LN, Ungvari GS. Prevalence of mental disorders in China. *Lancet Psychiatry*. (2019) 6:467–8. doi:10.1016/S2215-0366(19)30128-2

19. Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001–05: an epidemiological survey. *Lancet*. (2009) 373:2041–53. doi:10.1016/S0140-6736(09)60660-7

20. Huang Y, Wang Y, Wang H, Liu Z, Yu X, Yan J, et al. Prevalence of mental disorders in China: a cross-sectional epidemiological study. *Lancet Psychiatry*. (2019) 6:221–24. doi:10.1016/S2215-0366(18)30511-X

21. Yin H, Xu G, Tian H, Yang G, Wardenaar KJ, Schoevers RA. The prevalence, age-of-onset and the correlates of DSM-IV psychiatric disorders in the Tianjin Mental Health Survey (TMHS). *Psychol Med*. (2018) 48:473–87. doi:10.1017/s0033291717001878

22. Shen YC, Zhang MY, Huang YQ, He YL, Liu ZR, Cheng H, et al. Twelve-month prevalence, severity, and unmet need for treatment of mental disorders in metropolitan China. *Psychol Med*. (2006) 36:257–67. doi:10.1017/S0033291705006367

23. Huang Y, Liu Z, Wang H, Guan X, Chen H, Ma C, et al. The China Mental Health Survey (CMHS): I. Background, aims and measures. *Soc Psychiatry Psychiatr Epidemiol*. (2016) 51:1559–69. doi:10.1007/s00127-016-1270-z

24. NBS. *Chinese Statistics Yearbook 2019*. Beijing, China: China Statistics Press (2019).

25. Keqing L, Ze C, Lijun C, Qinpu J, Guang S, Haoran W, et al. Epidemiological survey of mental disorders in the people aged 18 and older in Hebei Province. *Asian J Psychiatr*. (2008) 1:51–5. doi:10.1016/j.ajp.2008.09.010

26. Xu G, Chen G, Zhou Q, Li N, Zheng X. Prevalence of Mental Disorders among Older Chinese People in Tianjin City. *Can J Psychiatry*. (2017) 62:778–86. doi:10.1177/0706743717727241

**AUTHOR CONTRIBUTIONS**

LS analyzed the data and wrote the manuscript. YZ was a major contributor in writing the manuscript. KL designed this study and gave important comments on the manuscript. LC, JL, LL, XS, YL, and LZ collected the data. All authors read and approved the final manuscript.

**FUNDING**

This research was supported by the National Natural Science Foundation of China (71603149 and 71974114). The funders had no role in the study design, data collection and analysis, writing the paper and the decision to submit the paper for publication.
34. Newcombe RG. Two-sided confidence intervals for the single proportion.

35. Fergusson DM, Horwood LJ, Miller AL, Kennedy MA. Life stress, 5-HTTLPR polymorphism, and the development of the Chinese scaled version. *Soc Psychiatry Psychiatr Epidemiol.* (1993) 28:124–9. doi: 10.1007/BF00801742

36. Kessler RC, Angermeyer M, Anthony JC, R相助, Demyttenaere K, Gayed KM. Comorbidity Survey Replication. *Arch Gen Psychiatry.* (2005) 62:617–27. doi: 10.1001/archpsyc.62.6.617

37. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* (2005) 62:617–27. doi: 10.1001/archpsyc.62.6.617

38. Jain M, Tandon S, Sharma A, Jain V, Rani Yadav N. Cross-Cultural adaptation, validity and reliability of a Hindi version of the Corah's Dental Anxiety Scale. *Health Promot Perspect.* (2016) 25:217–44. doi: 10.1017/S2045796015000566

39. Safer DJ, Rajakannan T, Barcusa M, Zito JM. Trends in subthreshold psychiatric diagnoses for youth in community treatment. *JAMA psychiatry.* (2015) 72:75–83. doi: 10.1001/jamapsychiatry.2014.1746

40. Rajakannan T, Safer DJ, Barcusa M, Zito JM. National Trends in Psychiatric Not Otherwise Specified (NOS) Diagnosis and Medication Use Among Adults in Outpatient Treatment. *Psychiatr Serv.* (2016) 67:289–95. doi: 10.1176/appi.ps.201500045

41. Topozoglu A, Binbay T, Ulas H, Elbi H, Tanik FA, Zagli N, et al. The epidemiology of major depressive disorder and subthreshold depression in Izmir, Turkey: Prevalence, socioeconomic differences, impairment and help-seeking. *J Affect Disord.* (2015) 181:78–86. doi: 10.1016/j.jad.2015.04.017

42. Ishikawa H, Kawakami N, Kessler RC. Emotional Distress in the World Health Organization's World Mental Health Survey Initiative. *World Psychiatry.* (2007) 6:168–76. doi: 10.1002/mp.1836

43. Lev-Ran S, Imtiaz S, Rehm J, Le Foll B. Exploring the association between lifetime prevalence of mental illness and transition from substance use to substance use disorders: results from the National Epidemiologic Survey of Alcohol and Related Conditions (NESARC). *Am J Addict.* (2013) 22:93–8. doi: 10.1111/j.1521-0391.2013.00304.x

44. Guo Y, Hu H, Liu Y, Leng Y, Gao X, Cui Q, et al. Gender differences in the relationship between alcohol consumption and insomnia in the northern Chinese population. *PLoS One.* (2018) 13:e0207392. doi: 10.1371/journal.pone.0207392

45. Yue Y, Hong L, Guo L, Gao X, Deng J, Huang J, et al. Gender differences in the association between cigarette smoking, alcohol consumption and depressive symptoms: a cross-sectional study among Chinese adolescents. *Sci Rep.* (2015) 5:17959. doi: 10.1038/srep17959

46. Mehta D, Rex-Haffner M, Sondergaard HB, Pinborg A, Binder EB, Frokjaer VG. Evidence for oestrogen sensitivity in perinatal depression: pharmacological sex hormone manipulation study. *Br J Psychiatry.* (2019) 215:519–27. doi: 10.1192/bjp.2018.234

47. Asselmann E, Kische H, Haring R, Hertel J, Schmidt CO, Nauck M, et al. Prospective associations of androgens and sex hormone-binding globulin with 12-month, lifetime and incident anxiety and depressive disorders in men and women from the general population. *J Affect Disord.* (2019) 245:905–11. doi: 10.1016/j.jad.2018.11.052

48. Asselmann E, Beesdo-Baum K, Hamm A, Schmidt CO, Hertel J, Grabe HJ, et al. Lifetime and 12-month prevalence estimates for mental disorders in northeastern Germany: findings from the Study of Health in Pomerania. *Eur Arch Psychiatry Clin Neurosci.* (2019) 269:341–50. doi: 10.1007/s00406-018-0911-5

49. Liu C, Zhang L, Ahmed F, Shahid M, Wang X, Wang Y, et al. Family Care, Economic Stress, and Depressive Symptoms Among Chinese Adults During the COVID-19 Outbreak: Differences by Urban and Rural Areas. *Front Psychiatry.* (2021) 12:700493. doi: 10.3389/fpsyt.2021.700493

50. Yerseyan I, Lohaus A. Stress and well-being among Turkish and German adolescents living in rural and urban areas. *Rural Remote Health.* (2014) 14:2695. doi: 10.22605/RRH2695

51. Salem T, Walters KA, Verducci JS, Fristad MA. Psychoeducational and skill-building interventions for emotion dysregulation. *Child Adolesc Psychiatr Clin N Am.* (2021) 30:611–22. doi: 10.1016/j.chc.2021.04.010

52. Naik SK. Management of bipolar disorders in women by nonpharmacological methods. *Indian J Psychiatry.* (2015) 57:5264–74. doi: 10.4103/0019-5545.161490

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher's Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

**Copyright © 2021 Sun, Zhang, Cui, Li, Li, Sun, Liu, Zhang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**